<div class="infobox infobox-gene">
<h3>NSD3</h3>
<table>
<tr><td><strong>Full Name</strong></td><td>Nuclear Receptor Binding SET Domain Protein 3</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>NSD3 (WHSC1L1)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>8p11.23</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[54904](https://www.ncbi.nlm.nih.gov/gene/54904)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[607083](https://omim.org/entry/607083)</td></tr>
<tr><td><strong>Ensembl</strong></td><td>[ENSG00000147548](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147548)</td></tr>
<tr><td><strong>UniProt</strong></td><td>[Q9BZ95](https://www.uniprot.org/uniprot/Q9BZ95)</td></tr>
<tr><td><strong>Protein</strong></td><td>Histone-lysine N-methyltransferase NSD3</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), intellectual disability, 8p11 myeloproliferative syndrome</td></tr>
</table>
</div>
<div class="infobox infobox-gene">
<h3>NSD3</h3>
<table>
<tr><td><strong>Full Name</strong></td><td>Nuclear Receptor Binding SET Domain Protein 3</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>NSD3 (WHSC1L1)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>8p11.23</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[54904](https://www.ncbi.nlm.nih.gov/gene/54904)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[607083](https://omim.org/entry/607083)</td></tr>
<tr><td><strong>Ensembl</strong></td><td>[ENSG00000147548](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147548)</td></tr>
<tr><td><strong>UniProt</strong></td><td>[Q9BZ95](https://www.uniprot.org/uniprot/Q9BZ95)</td></tr>
<tr><td><strong>Protein</strong></td><td>Histone-lysine N-methyltransferase NSD3</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), intellectual disability, 8p11 myeloproliferative syndrome</td></tr>
</table>
</div>
NSD1 is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
NSD3 (also known as WHSC1L1) encodes a histone lysine methyltransferase of the nuclear receptor SET domain (NSD) family that catalyzes mono- and dimethylation of histone H3 at lysine 36 (H3K36me1/2). Together with its paralogs [NSD1](/genes/nsd1) and [NSD2](/genes/nsd2), NSD3 is responsible for the majority of H3K36me2 deposition genome-wide, a histone mark associated with active transcription and chromatin domain organization [@li2021] [@piunti2016].
NSD3 is a 1437-amino-acid multidomain protein containing:
NSD3 plays a critical role in neural chromatin organization through its H3K36me2 methyltransferase activity. H3K36me2 is essential for maintaining the transcriptional programs of differentiated [neurons](/entities/neurons). Loss of NSD3 function disrupts the balance between active (H3K36me2) and repressive (H3K27me3) chromatin domains, leading to inappropriate silencing of neuronal genes and derepression of developmental programs [@shen2022].
In the aging brain, progressive decline in H3K36 methylation is a hallmark of epigenetic aging. NSD3 dysregulation contributes to this age-related chromatin deterioration, creating a permissive environment for neurodegeneration. H3K36me2 depletion at neuronal gene bodies causes aberrant intragenic transcription and cryptic transcription initiation, producing toxic antisense and noncoding transcripts [@rahman2011].
The NSD3-short isoform functions as a critical adaptor between the BET bromodomain protein [BRD4](/genes/brd4) and chromatin. NSD3S bridges BRD4 to H3K36me-marked chromatin through its PWWP domain, enabling BRD4-dependent transcriptional activation at super-enhancers. In [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes), this BRD4–NSD3 axis drives the expression of pro-inflammatory gene programs including [IL-1β](/genes/il1b), [TNF-α](/genes/tnf), and [IL-6](/genes/il6) [@jansen2019].
In [Alzheimer's disease](/diseases/alzheimers-disease), chronic activation of the BRD4–NSD3 inflammatory axis in reactive microglia surrounding amyloid plaques sustains the neuroinflammatory cascade that drives synaptic loss and neuronal death. BET inhibitors such as JQ1 and I-BET762, which disrupt the BRD4–NSD3–chromatin complex, show neuroprotective effects in AD mouse models by suppressing microglial inflammatory transcription [@sotofeliciano2023].
NSD3-mediated H3K36me2 is required for efficient DNA double-strand break repair via homologous recombination. The PWWP domain of 53BP1 recognizes H3K36me2 to promote non-homologous end joining pathway choice. In post-mitotic neurons, which cannot use homologous recombination, proper H3K36me2 levels are critical for accurate DNA repair. NSD3 loss leads to accumulation of DNA damage, activation of [p53](/entities/tp53)-dependent [apoptosis](/entities/apoptosis), and progressive neuronal loss [@zhang2019].
NSD3 regulates the expression of key synaptic genes including those encoding glutamate receptors, scaffolding proteins, and synaptic vesicle machinery. H3K36me2 deposited by NSD3 at synaptic gene bodies facilitates their co-transcriptional processing, including alternative splicing of activity-dependent exons. Disruption of NSD3 function leads to aberrant splicing of synaptic transcripts and impaired synaptic plasticity [@wagner2020].
NSD3 is broadly expressed throughout the brain, with highest levels in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and cerebellum. During development, NSD3 expression peaks during the period of active neurogenesis and synaptogenesis. In the adult brain, NSD3 is expressed in both neurons and glial cells, with particularly high levels in hippocampal CA1 pyramidal neurons—a population vulnerable to [Alzheimer's disease](/diseases/alzheimers-disease)—and in dopaminergic neurons of the substantia nigra, which are lost in [Parkinson's disease](/diseases/parkinsons-disease) [@lucioeterovic2010].
Single-cell RNA sequencing studies show that NSD3 expression is highest in excitatory neurons and oligodendrocytes, with moderate expression in astrocytes and microglia. Notably, NSD3-short (the BRD4-binding isoform) is preferentially expressed in activated microglia, consistent with its role in inflammatory gene regulation [@bennett2020].
| Variant | Type | Association | Reference |
|---------|------|-------------|-----------|
| 8p11.23 amplification | CNV | Intellectual disability, developmental delay | [Rossi et al., 2017](https://doi.org/10.1002/ajmg.a.38222) |
| rs2019960 | SNP | Nominal AD risk association (GWAS) | [Jansen et al., 2019](https://doi.org/10.1038/s41588-018-0311-9) |
| NSD3 T1232A | Missense | Gain-of-function, enhanced H3K36me2 | [Li et al., 2021](https://doi.org/10.1038/s41586-021-03528-w) |
The BRD4–NSD3 interaction represents a promising therapeutic target for neuroinflammatory conditions. Several strategies are under investigation:
The following diagram shows the key molecular relationships involving NSD3 (Nuclear Receptor Binding SET Domain Protein 3) discovered through SciDEX knowledge graph analysis: